Therapeutics and point of care lateral-flow test for virus and antibodies using tagged assembled proteins
AssigneeNew York University
InventorsJin Kim Montclare, Farbod Mahmoudinobar, Kamia Punia, Dustin Robert Britton
Life of this patent
Estimating the term…
Abstract
Provided is a multivalent protein that targets interaction of SARS-CoV-2 spike receptor binding domain (RBD) with the human angiotensin-converting enzyme 2 (ACE2) receptor protein. The multivalent proteins may also be used to treat subjects having cancer and/or a disease and/or viral infection. Also presented is a multiplex lateral flow test strips for simultaneous detection of the virus and viral antibodies.
Claims10
A protein comprising one or more X1 blocks, X2 blocks, and X3 blocks, wherein the X1 block is a coiled-coil domain, the X2 block is a linker, and the X3 block is a binding domain for a target protein, wherein the X1, X2, and X3 blocks are oriented from the N to C-terminus as (X1)a-(X2)b-(X3)c or (X3)c-(X2)b-(X1)a, wherein a, b, and c are the number of repeat units for the blocks, wherein a, b, and c are each independently 1 to 50,
- wherein X3 is IEEQAKTFLDKFNGEELLRALDQVN (SEQ ID NO:39) or a sequence having at least 85% identity thereto and X1 comprises the following sequence:
- (SEQ ID NO:
- 3)
- MRGSHHHHHHGSACELAATATATATATATAACGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWKAAAK;
- (SEQ ID NO:
- 4)
- MRGSHHHHHHGSASELAATATATATATATAASGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWKAAAK;
- (SEQ ID NO:
- 5)
- MRGSHHHHHHGSACELAATATATATATATAACGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWK;
- (SEQ ID NO:
- 6)
- MRGSHHHHHHGSASELAATATATATATATAASGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWK;
- (SEQ ID NO:
- 172)
- MRGSHHHHHHGSACELAATATATATATATAACGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNT,
- (SEQ ID NO:
- 173)
- MRGSHHHHHHGSASELAATATATATATATAASGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNT,
- (SEQ ID NO:
- 8)
- GSACELAATATATATATATAACGDLAPQMLRELQETNAALQDVRELLRQQ
- VKEITFLKNTLLEIWKAAAK;
- (SEQ ID NO:
- 9)
- GSASELAATATATATATATAASGDLAPQMLRELQETNAALQDVRELLRQQ
- VKEITFLKNTLLEIWKAAAK;
- (SEQ ID NO:
- 10)
- GSACELAATATATATATATAACGDLAPQMLRELQETNAALQDVRELLRQQ
- VKEITFLKNTLLEIWK;
- (SEQ ID NO:
- 11)
- GSASELAATATATATATATAASGDLAPQMLRELQETNAALQDVRELLRQQ
- VKEITFLKNTLLEIWK;
- (SEQ ID NO:
- 174)
- MRGSHHHHHHGSACELAATATATATATATAACGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWK,
- (SEQ ID NO:
- 175)
- MRGSHHHHHHGSASELAATATATATATATAASGDLAPQMLRELQETNAAL
- QDVRELLRQQVKEITFLKNTLLEIWK,
- (SEQ ID NO:
- 12)
- DLAPQMLRELQETNAALQDVRELLRQQVKEITFLKNTLLEIWKAAK,
- (SEQ ID NO:
- 13)
- DLAPQMLRELQETNAALQDVRELLRQQVKEITFLKNTLLEIWK,
- (SEQ ID NO:
- 14)
- DLAPQMLRELQETNAALQDVRELLRQQVKEITFLKNT,
- or
- a sequence having at least 85% identity with any one of SEQ ID NOs:3-6, 8-14, and 172-175.
Dependencies are inferred from the claim text.